Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Pharm Ther. 1996 Aug;21(4):195-9.

Therapeutic advances: beta-interferon for multiple sclerosis.

Author information

1
Department of Pharmacy Policy and Practice, Keele University, Staffs.

Abstract

Multiple sclerosis (MS) is a very distressing condition for which there is no effective treatment. Two randomized double-blind placebo-controlled trials of beta-interferon in mildly disabled patients with relapsing remitting MS have been published. Although promising, beta-interferon is not a cure for MS and the clinical significance of the small effect of beta-interferon on disease progression is not known. The high cost of beta-interferon, the distressing nature of MS and the small benefit demonstrated in clinical trials mean that purchasers and clinicians will face hard decisions in managing the introduction of these drugs.

PMID:
8933292
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center